one
import
clinic
applic
intraven
immunoglobulin
ivig
suppli
broad
spectrum
antibodi
patient
antibodydefici
throughout
live
patient
inherit
primari
antibodi
defici
treat
rel
high
dose
ivig
patient
develop
secondari
antibodi
defici
diseas
diseaserel
therapi
may
also
receiv
highdos
ivig
prolong
period
time
observ
platelet
count
rise
circul
treatment
immun
thrombocytopen
purpura
itp
highdos
ivig
earli
door
open
explor
potenti
highdos
ivig
sever
nonimmunodefici
diseas
singl
multipl
cours
highdos
ivig
success
use
treat
wide
varieti
autoimmun
disord
review
see
ref
mechan
action
ivig
wide
varieti
diseas
recent
review
regular
exposur
larg
quantiti
human
plasma
protein
carri
risk
infect
bloodborn
pathogen
increas
pathogen
safeti
ivig
without
diminish
clinic
efficaci
high
prioriti
transmiss
homolog
serum
hepat
whole
blood
plasma
serum
great
concern
develop
plasma
fraction
procedur
produc
human
serum
albumin
world
war
ii
yellow
fever
vaccin
stabil
human
serum
produc
case
hepat
american
militari
personnel
epidemiolog
investig
strongli
suggest
pool
human
plasma
present
higher
risk
hepat
transmiss
whole
blood
attribut
increas
probabl
pool
plasma
would
contamin
one
sever
donor
plasma
pool
blood
donat
use
produc
albumin
effort
initi
inactiv
hepat
virus
human
serum
albumin
solut
gelli
cowork
report
hepat
transmiss
albumin
elimin
heat
h
procedur
possibl
discoveri
mm
acetyltryptophan
mm
sodium
capryl
increas
heat
resist
albumin
unfortun
plasma
protein
solut
inactiv
heat
earli
attempt
inactiv
virus
highrisk
product
unsuccess
immunoglobulin
produc
cold
ethanol
fraction
found
low
risk
viru
transmiss
similar
heat
albumin
solut
reason
unknown
percept
chang
lane
report
ivig
produc
cold
ethanol
fraction
transmit
nona
nonb
hepat
time
human
immunodefici
viru
hiv
isol
proven
transmiss
blood
blood
product
although
confirm
hiv
transmiss
ivig
emerg
hiv
report
nona
nonb
hepat
transmiss
ivig
product
other
caus
manufactur
regulatori
agenc
examin
exist
ivig
manufactur
process
capac
elimin
virus
develop
dedic
viru
inactiv
procedur
ivig
product
also
initi
discov
rel
low
risk
viru
transmiss
immunoglobulin
caus
remov
virus
manufactur
product
two
mechan
partit
inactiv
year
procedur
base
mechan
develop
refin
viru
filtrat
third
gentl
mechan
ad
remov
virus
base
size
tion
elimin
base
size
accord
mode
action
procedur
select
biolog
base
effect
limit
must
consid
care
achiev
highest
possibl
net
safeti
pathogen
safeti
well
protein
integr
product
yield
commonli
use
procedur
experiment
elimin
procedur
introduc
follow
subhead
precipit
classic
plasma
fraction
class
protein
precipit
separ
protein
remain
solut
either
centrifug
filtrat
virusesshould
presentar
frequent
precipit
along
protein
fig
henc
may
end
wast
fraction
effect
virusremov
step
immunoglobulin
ig
g
product
occur
fraction
precipit
fraction
iiiii
demonstr
experiment
valid
studi
almost
viru
cohn
fraction
iiiii
remov
precipit
fraction
iii
kistlernitschmann
precipit
b
wast
fraction
contain
iga
igm
plasminogen
protein
fig
virusremov
capac
precipit
step
depend
surfac
properti
virus
well
solut
composit
filter
aid
salt
ph
etc
particular
role
assign
filter
aid
need
allow
filtrat
protein
precipit
adsorb
virus
effici
chromatographi
may
potent
virusremov
step
newer
manufactur
process
plasma
deriv
also
use
chromatographi
virusremov
step
virusremov
capac
chromatographi
step
depend
surfac
properti
virus
chromatographi
resin
solut
composit
ph
salt
etc
chromatographi
use
viru
remov
crucial
show
reproduc
lifespan
resin
column
properli
sanit
product
cycl
viru
inactiv
capac
usual
describ
log
reduct
factor
lrf
inactiv
kinet
rapid
inactiv
kinet
consid
indic
robust
process
fig
challeng
develop
viru
inactiv
procedur
protein
solut
inactiv
virus
without
harm
therapeut
protein
noncoval
bond
involv
viru
assembl
maintain
protein
nativ
biolog
activ
threedimension
structur
conform
consequ
process
inactiv
virus
may
also
denatur
protein
protein
withstand
small
chang
conform
without
lose
biolog
activ
may
renatur
spontan
protein
lose
biolog
activ
minor
chang
conform
denatur
temperatur
protein
sharpli
defin
differ
protein
heat
definit
time
temperatur
denatur
temperatur
particular
protein
use
protein
purif
procedur
inactiv
virus
presenc
substrat
enzym
heat
temperatur
higher
absenc
substrat
pasteur
use
inactiv
predominantli
envelop
virus
wide
varieti
plasma
deriv
howev
also
effect
nonenvelop
virus
eg
viru
ref
dryheat
treatment
broadli
appli
coagul
factor
final
contain
inactiv
envelop
nonenvelop
virus
report
low
suscept
bovin
parvoviru
bpv
canin
parvoviru
cpv
observ
circumst
transmiss
viru
dryheattr
coagul
factor
also
report
mani
report
show
inactiv
envelop
virus
low
ph
eg
ph
presenc
absenc
limit
amount
pepsin
nonenvelop
recent
found
suscept
condit
anim
parvoviru
mice
minut
viru
mmv
resist
treatment
viru
inactiv
low
ph
base
conform
chang
viral
structur
protein
mainli
membraneassoci
glycoprotein
envelop
virus
capsid
protein
nonenvelop
virus
presenc
lipid
envelop
bloodborn
virus
make
uniqu
suscept
inactiv
chemic
dissolv
dissoci
lipid
solvent
deterg
although
protein
also
denatur
solvent
deterg
expos
low
level
limit
period
time
without
signific
irrevers
effect
structur
function
observ
exploit
horowitz
cowork
develop
viru
inactiv
process
involv
addit
solvent
deterg
solventdeterg
viru
inactiv
soon
appli
wide
varieti
plasma
protein
consid
risk
transmit
virus
hepat
c
transmiss
ivig
report
solventdeterg
viru
inactiv
incorpor
sever
ivig
manufactur
process
disrupt
viral
lipid
envelop
action
capryl
similar
solventdeterg
treatment
nonion
capryl
shown
inactiv
sever
envelop
virus
mechan
also
appli
recent
establish
ivig
manufactur
process
energi
ultraviolet
c
uvc
light
nm
correspond
ev
strong
enough
break
atom
bond
cc
bond
dissoci
energi
env
ev
uvc
inactiv
pathogen
disruptingmodifi
nucleic
acid
protein
molecul
unspecif
inactiv
procedur
may
also
harm
therapeut
protein
loss
protein
yield
protein
activ
gener
neoantigen
must
care
investig
inactiv
uvc
may
interest
manufactur
fragil
larg
protein
inactiv
envelop
nonenvelop
virus
also
achiev
design
stateoftheart
uvc
devic
recent
describ
propos
broadli
effect
viru
inactiv
method
biolog
although
much
higher
dose
must
appli
viru
inactiv
biolog
kgi
steril
medic
devic
kgi
function
properti
experiment
ivig
shown
maintain
like
uvc
effect
broad
rang
virus
loss
protein
yield
protein
activ
gener
neoantigen
owe
must
care
investig
viral
genom
ideal
target
inactiv
virus
without
damag
therapeut
protein
approach
chosen
intercal
eg
psoralen
ref
electrophil
ethyleneimin
ref
chemic
activ
coval
modifi
predominantli
nucleic
acid
treatment
never
exclus
select
nucleic
acid
therefor
risk
gener
neoantigen
chemic
modif
protein
must
care
investig
true
chemic
inactiv
virus
modif
protein
ref
unspecif
chemic
modif
singlet
oxygen
use
sensit
methylen
blue
filtrat
long
use
remov
bloodborn
pathogen
plasma
product
steril
germ
filtrat
filter
remov
bacteria
fungi
process
effect
develop
filter
pore
size
small
enough
remov
virus
logic
consequ
develop
virusremov
filter
therapeut
protein
solut
handicap
need
process
larg
volum
reason
flow
rate
initi
problem
resolv
earli
viral
safeti
plasma
product
improv
implement
viru
filtrat
process
scale
viru
filtrat
simpl
robust
nondestruct
process
add
size
exclus
new
mechan
convent
viru
inactiv
partit
discrimin
envelop
nonenvelop
virus
viru
filtrat
potenti
remov
broadest
rang
pathogen
fig
term
viru
filtrat
becom
accept
nomenclatur
previous
call
nanofiltr
viru
filtrat
becom
gener
accept
effici
robust
method
remov
virus
larger
pore
size
filter
howev
differ
observ
remov
studi
virus
size
smaller
pore
size
viru
filter
addit
pore
size
factor
composit
immunoglobulin
ig
g
solut
model
viru
use
may
play
role
ig
solut
may
contain
antibodi
interact
viru
lead
retent
virus
smaller
pore
size
elimin
capac
small
virus
studi
sever
author
emerg
reemerg
virus
may
defin
virus
newli
appear
popul
exist
previous
rapidli
increas
incid
geograph
rang
past
centuri
develop
world
believ
diseas
includ
emerg
diseas
would
regress
futur
vaccin
program
erad
smallpox
almost
elimin
polio
reliev
burden
childhood
diseas
introduct
antibiot
mani
bacteri
diseas
vanquish
improv
sanitari
condit
medic
care
also
contribut
decreas
devast
infecti
diseas
world
chang
continu
live
phase
call
global
socioeconom
impact
global
humankind
direct
indirect
impact
emerg
pathogen
three
factor
import
emerg
pathogen
occur
fig
microbehost
interact
adapt
microb
environ
coloni
environ
potenti
host
global
increas
longdist
trade
travel
urban
often
dens
impoverish
settlement
pressur
land
reserv
migrat
land
climat
chang
also
influenc
environ
host
microb
therefor
expect
new
resurg
pathogen
futur
howev
countermeasur
treatment
prophylaxi
surveil
capabl
rapidli
investig
react
new
threat
global
scale
also
evolv
past
yr
therefor
possibl
make
predict
sever
futur
outbreak
emerg
pathogen
promin
recent
exampl
emerg
viru
sever
acut
respiratori
syndrom
sar
coronaviru
novemb
first
known
case
atyp
pneumonia
occur
foshan
citi
guangdong
provinc
china
march
sever
atyp
pneumonia
spread
three
contin
countri
world
health
organ
set
global
network
expedit
detect
caus
agent
develop
robust
reliabl
diagnost
test
pool
clinic
knowledg
symptom
diagnosi
manag
studi
sar
epidemiolog
school
close
thousand
peopl
put
quarantin
affect
area
travel
recommend
issu
airlin
start
screen
passeng
symptom
exactli
mo
establish
laboratori
network
announc
conclus
identif
sar
caus
agent
entir
new
coronaviru
unlik
human
anim
member
famili
coronavirida
juli
last
known
chain
transmiss
interrupt
taiwan
coordin
control
measur
recommend
includ
earli
identif
isol
patient
vigor
contact
trace
manag
close
contact
public
inform
educ
encourag
prompt
report
symptomscertainli
togeth
portion
luckwer
effect
overcom
sar
epidem
exampl
reemerg
viru
west
nile
viru
wnv
unit
state
within
yr
wnv
spread
east
coast
west
coast
bird
primari
amplifi
host
viru
maintain
birdmosquitobird
cycl
infect
mammal
deadend
infect
reason
rapid
dynam
wnv
epidem
north
america
viru
found
favor
environ
appropri
vector
host
two
exampl
show
chang
host
environ
microb
relationship
may
contribut
emerg
reemerg
virus
fig
learn
lesson
hiv
hepat
c
transmiss
plasma
process
industri
today
cope
well
envelop
larg
virus
virus
futur
concern
small
nonenvelop
one
virus
difficult
inactiv
use
physicochem
treatment
current
promis
measur
probabl
viru
filtrat
repres
class
virus
alreadi
present
human
popul
picornavirida
eg
hepat
viru
parvovirida
eg
circovirida
eg
tt
viru
sen
viru
circul
ubiquit
hepat
known
caus
agent
hepat
may
caus
varieti
ill
manifest
depend
immunolog
hematolog
state
host
healthi
immunocompet
individu
infect
mostli
asymptomat
caus
erythema
infectiosum
replic
strictli
depend
divid
erythroid
progenitor
cell
therefor
infect
individu
underli
hematolog
disord
may
show
transient
aplast
crisi
immunocompromis
person
may
persist
infect
manifest
pure
red
cell
aplasia
chronic
anemia
nonhematolog
disord
rheumat
neurolog
manifest
report
pregnant
women
special
risk
infect
may
lead
hydrop
fetali
human
diseas
definit
link
circovirus
although
search
associ
diseas
goe
alreadi
describ
submerg
viral
threat
highli
sensit
techniqu
avail
today
revers
situat
may
identifi
pathogen
without
know
diseas
instead
know
diseas
pathogen
possibl
prospect
investig
potenti
threat
emerg
pathogen
howev
emin
import
keep
mind
commens
nonpathogen
microb
prevail
number
human
pathogen
focu
small
nonenvelop
virus
potenti
emerg
owe
histori
circul
date
awar
emerg
human
pathogen
characterist
describ
howev
occur
anim
classic
exampl
emerg
viru
type
canin
parvoviru
cpv
type
member
famili
parvovirida
parvovirus
infect
differ
vertebr
host
tissu
constrict
cell
must
divid
state
allow
viru
replic
shift
speci
tropism
felin
panleukopenia
viru
fpv
recent
observ
review
see
ref
result
emerg
cpv
new
pathogen
dog
subsequ
rapid
global
spread
event
occur
limit
number
aminoacid
chang
involv
transferrin
receptor
tfr
bind
surround
threefold
spike
viru
evolv
follow
year
replic
cat
b
replic
effici
cat
caus
infect
fpv
substitut
rate
capsid
protein
calcul
nucleotid
year
time
less
rna
virus
anoth
parvoviru
high
mutat
frequenc
report
mmv
lopezbueno
et
al
report
mutat
frequenc
substitut
per
nucleotid
round
replic
vivo
vitro
replic
presenc
neutral
monoclon
antibodi
studi
mutat
frequenc
close
one
report
retrovirus
presenc
monoclon
antibodi
bound
highli
antigen
threefold
spike
virus
escap
antibodi
neutral
select
enrich
within
three
passag
vivo
experi
sever
combin
immunodefici
mice
treat
antibodi
day
postinfect
escap
mutant
also
select
viru
stock
use
experi
cultiv
singl
mmv
clone
presenc
virus
resist
neutral
antibodi
alreadi
stock
prepar
show
consider
divers
clonal
popul
parvovirus
phenomenon
gener
call
viral
quasispeci
wellknown
retroviru
field
high
genom
variabl
also
describ
isol
persist
infect
patient
proteinsequ
deviat
refer
isol
au
region
describ
threefold
spike
parvovirus
highli
antigen
involv
mani
interact
differ
hostcel
receptor
capac
control
host
tropism
cat
dog
fpv
cpv
via
interact
tfr
tissu
tropism
mmv
leukocyt
mmv
p
fibroblast
tissu
tropism
pathogen
kress
nonpathogen
strain
porcin
parvoviru
may
sever
reason
high
mutat
frequenc
first
although
parvoviru
dna
replic
strictli
depend
host
replic
factor
sphase
cell
cycl
mechan
unidirect
lead
strand
dna
synthesi
differ
cellular
semiconserv
dna
replic
lead
lag
strand
also
observ
parvoviru
dna
replic
use
distinct
replic
bodi
ident
nuclear
dna
replic
bodi
may
reason
parvoviru
dna
replic
less
accur
cellular
dna
replic
second
highli
antigen
structur
threefold
spike
must
high
select
pressur
host
defens
third
low
pressur
neg
select
may
addit
reason
observ
mutat
frequenc
appar
parvovir
capsid
may
toler
certain
variabl
without
neg
impact
infect
capsid
stabil
figur
show
high
degre
variabl
amino
acid
two
stretch
make
threefold
spike
erythroviru
capsid
mention
sequenc
deposit
uniprot
databas
retriev
low
stringenc
wublast
search
search
matrix
quasispeci
behavior
parvovirus
provid
pool
genet
varianc
rapidli
adapt
select
pressur
may
also
parvovirus
lurk
anim
kingdom
may
jump
human
without
mutat
genom
describ
brown
et
al
simian
parvoviru
spv
erythroviru
macaqu
spv
belong
genu
erythrovirus
caus
similar
diseas
pattern
macaqu
human
author
report
handler
spvposit
macaqu
coloni
carri
antibodi
spv
spvspecif
also
antibodi
detect
individu
interestingli
blood
donor
carri
spvspecif
antibodi
spv
abl
infect
human
cell
small
nonenvelop
virus
potenti
appear
emerg
pathogen
famili
picornavirida
circovirida
picornavirus
wide
distribut
human
popul
although
mani
infect
nonappar
picornavirus
etiolog
agent
ill
myocard
acut
neurolog
diseas
eg
asept
mening
enceph
poliomyelit
syndrom
pancreat
hand
foot
mouth
diseas
despit
almost
complet
extinct
polio
viru
still
occur
area
world
member
circovirida
famili
howev
current
submerg
pathogen
initi
suspect
link
human
diseas
establish
genom
virus
consist
circular
singlestrand
dna
replic
still
wellknown
howev
tt
viru
describ
circul
quasispeci
owe
high
degre
sequenc
variabl
plasmaderiv
therapeut
lifesav
product
howev
like
biolog
carri
inher
risk
transmit
pathogen
current
viru
elimin
method
use
plasma
process
industri
contribut
high
safeti
standard
medicin
method
also
prove
effect
recent
encount
emerg
virus
sar
wnv
nevertheless
viru
transmiss
may
still
occur
report
clot
factor
fibrin
sealant
effort
increas
repertoir
countermeasur
small
nonenvelop
virus
ongo
outlin
increas
frequenc
emerg
virus
may
expect
futur
socioeconom
ecolog
chang
howev
impact
would
blood
safeti
difficult
estim
thu
possibl
emerg
virus
appear
plasma
donor
real
worst
possibl
case
would
emerg
small
nonenvelop
viru
alreadi
know
circul
small
nonenvelop
virus
harbor
capac
switch
host
tissu
tropism
exist
although
today
ig
safer
ever
plasma
process
indu
tri
highli
vigil
prepar
futur
sensit
techniqu
avail
studi
diagnosi
virus
must
appli
proactiv
even
virus
consid
human
pathogen
virus
need
studi
cellular
molecular
level
identifi
vulner
gener
basi
develop
appropri
remov
inactiv
method
